

New drug  
development  
and value  
creation

*Uniquely translating university assets to  
innovative products*

© 2014 Bessor Pharma LLC

An Innovative Biomarker Driven  
Anticancer Antibody

# Bessor Pharma

- Develops promising therapeutic assets from universities
- Deliver proof of concept, clinical ready packages for license or sale to pharma
- Utilize a fully integrated drug development/ business network; top R and D team
- Focus on immuno-inflammation, immuno-oncology


# Renalase as a novel cancer target

- Elevated expression in cancer and increased levels correlate with poor survival
  - Melanoma, pancreatic, bladder, NSCLC
- Overexpressed in animal models
- Released by tumor-associated macrophages
- Receptor activation promotes cytoprotection; increases cell survival in cancer.

# Renalase deletion blunts lung tumor growth in mouse metastatic melanoma model




Wild type mouse with normal renalase levels



Renalase knock-out mouse; no renalase

# Anti-Renalase antibody active in checkpoint inhibitor resistant mouse melanoma model



Need N=5/group x 3

# Anti-renalase antibody development progress

- Therapeutic antibody development
  - In vitro, and in vivo activity in melanoma and pancreatic cancer
  - Studies in other hard to treat cancers underway
  - Active in checkpoint inhibitor resistant melanoma models
  - Humanization under way
- Renalase assay being developed with potential as a biomarker
- Seeking partners to accelerate development

New drug  
development  
and value  
creation

*Uniquely translating university assets to  
innovative products*

Mark Roffman, PhD  
VP Development & Regulatory Affairs  
mroffman@bessorpharma.com